- Stocks
- Healthcare
- NASDAQ: RVMD

Price (delayed)

$23.33

Market cap

$2.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.24

Enterprise value

$2.26B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities

The debt has contracted by 3.6% YoY

The company's equity rose by 23% YoY but it fell by 10% QoQ

RVMD's quick ratio is down by 19% since the previous quarter but it is up by 6% year-on-year

Revolution Medicines's net income has decreased by 35% YoY and by 12% from the previous quarter

The gross profit has declined by 11% since the previous quarter and by 11% year-on-year

What are the main financial stats of RVMD

Market
Valuations
Earnings

Shares outstanding

109.56M

Market cap

$2.56B

Enterprise value

$2.26B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.04

Price to sales (P/S)

97.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

86.3

Revenue

$26.17M

EBIT

-$335.33M

EBITDA

-$326.28M

Free cash flow

-$300.09M

Per share
Balance sheet
Liquidity

EPS

-$3.24

Free cash flow per share

-$2.75

Book value per share

$7.67

Revenue per share

$0.24

TBVPS

$8.35

Total assets

$984.23M

Total liabilities

$146.77M

Debt

$62.85M

Equity

$837.46M

Working capital

$738.93M

Debt to equity

0.08

Current ratio

9.64

Quick ratio

9.54

Net debt/EBITDA

0.91

Margins
Efficiency
Dividend

EBITDA margin

-1,246.9%

Gross margin

100%

Net margin

-1,266.2%

Operating margin

-1,409.8%

Return on assets

-33.6%

Return on equity

-38.9%

Return on invested capital

-58.6%

Return on capital employed

-37.3%

Return on sales

-1,281.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Revolution Medicines stock price performed over time

Intraday

3.87%

1 week

8.82%

1 month

27.14%

1 year

-1.1%

YTD

-2.06%

QTD

-15.72%

How have Revolution Medicines's revenue and profit performed over time

Revenue

$26.17M

Gross profit

$26.17M

Operating income

-$368.91M

Net income

-$331.34M

Gross margin

100%

Net margin

-1,266.2%

Revolution Medicines's operating margin has plunged by 67% YoY and by 29% from the previous quarter

The net margin has plunged by 53% YoY and by 26% from the previous quarter

RVMD's operating income is down by 48% year-on-year and by 14% since the previous quarter

Revolution Medicines's net income has decreased by 35% YoY and by 12% from the previous quarter

What is Revolution Medicines's growth rate over time

What is Revolution Medicines stock price valuation

P/E

N/A

P/B

3.04

P/S

97.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

86.3

The EPS has declined by 3.8% since the previous quarter

The company's equity rose by 23% YoY but it fell by 10% QoQ

The stock's price to sales (P/S) is 20% more than its last 4 quarters average of 81.4

The revenue has declined by 11% since the previous quarter and by 11% year-on-year

How efficient is Revolution Medicines business performance

The return on sales has dropped by 54% year-on-year and by 28% since the previous quarter

RVMD's ROIC is down by 25% year-on-year and by 15% since the previous quarter

RVMD's ROA is down by 7% QoQ

Revolution Medicines's return on equity has increased by 7% YoY but it has decreased by 7% QoQ

What is RVMD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RVMD.

How did Revolution Medicines financials performed over time

RVMD's total assets is up by 19% year-on-year but it is down by 8% since the previous quarter

RVMD's quick ratio is down by 19% since the previous quarter but it is up by 6% year-on-year

The debt is 92% less than the equity

The company's equity rose by 23% YoY but it fell by 10% QoQ

The debt to equity has contracted by 20% YoY but it has grown by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.